Lee Han-Soo writing for Korean Biomedical Review reports that Korean biopharma Daewoong Pharmaceutical presented tow of its new candidates at the American College of Rheumatology.  The two candidates:

DWN12088:    A fibrosis treatment

DWP213388:  A dual target autoimmune therapy

Park Joon-seok, Director of Daewoong’s New Drug Research Center states, “the results of the studies demonstrate the efficacy of the drug on rheumatic diseases” and continued “the company will focus on research and development of the two drugs.”  Lee Han-soo reports that Daewoong will conduct global phase 1 clinical trials next year.

Source: Korean Biomedical Review

Pin It on Pinterest